Logo image of CKPT

CHECKPOINT THERAPEUTICS INC (CKPT) Stock Fundamental Analysis

NASDAQ:CKPT - Nasdaq - US1628282063 - Common Stock - Currency: USD

4.26  +0.03 (+0.71%)

After market: 4.2705 +0.01 (+0.25%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CKPT. CKPT was compared to 556 industry peers in the Biotechnology industry. CKPT may be in some trouble as it scores bad on both profitability and health. CKPT has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CKPT has reported negative net income.
CKPT had a negative operating cash flow in the past year.
CKPT had negative earnings in each of the past 5 years.
CKPT had a negative operating cash flow in each of the past 5 years.
CKPT Yearly Net Income VS EBIT VS OCF VS FCFCKPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CKPT has a worse Return On Assets (-752.78%) than 97.67% of its industry peers.
Industry RankSector Rank
ROA -752.78%
ROE N/A
ROIC N/A
ROA(3y)-729.34%
ROA(5y)-468.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CKPT Yearly ROA, ROE, ROICCKPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500

1.3 Margins

CKPT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CKPT Yearly Profit, Operating, Gross MarginsCKPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

0

2. Health

2.1 Basic Checks

CKPT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CKPT has been increased compared to 5 years ago.
There is no outstanding debt for CKPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CKPT Yearly Shares OutstandingCKPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CKPT Yearly Total Debt VS Total AssetsCKPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

CKPT has an Altman-Z score of -85.21. This is a bad value and indicates that CKPT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CKPT (-85.21) is worse than 96.42% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -85.21
ROIC/WACCN/A
WACCN/A
CKPT Yearly LT Debt VS Equity VS FCFCKPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 0.37 indicates that CKPT may have some problems paying its short term obligations.
The Current ratio of CKPT (0.37) is worse than 93.74% of its industry peers.
CKPT has a Quick Ratio of 0.37. This is a bad value and indicates that CKPT is not financially healthy enough and could expect problems in meeting its short term obligations.
CKPT has a worse Quick ratio (0.37) than 93.20% of its industry peers.
Industry RankSector Rank
Current Ratio 0.37
Quick Ratio 0.37
CKPT Yearly Current Assets VS Current LiabilitesCKPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

CKPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.43%, which is quite impressive.
Looking at the last year, CKPT shows a very negative growth in Revenue. The Revenue has decreased by -60.19% in the last year.
The Revenue for CKPT have been decreasing by -52.58% on average. This is quite bad
EPS 1Y (TTM)53.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.42%
Revenue 1Y (TTM)-60.19%
Revenue growth 3Y-46.65%
Revenue growth 5Y-52.58%
Sales Q2Q%N/A

3.2 Future

CKPT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.84% yearly.
CKPT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 711.65% yearly.
EPS Next Y87.52%
EPS Next 2Y67.51%
EPS Next 3Y85.74%
EPS Next 5Y31.84%
Revenue Next Year300659%
Revenue Next 2Y11555.7%
Revenue Next 3Y3960.1%
Revenue Next 5Y711.65%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CKPT Yearly Revenue VS EstimatesCKPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CKPT Yearly EPS VS EstimatesCKPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

CKPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 3.70, which indicates a rather cheap valuation of CKPT.
Based on the Price/Forward Earnings ratio, CKPT is valued cheaper than 98.57% of the companies in the same industry.
CKPT is valuated cheaply when we compare the Price/Forward Earnings ratio to 37.64, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 3.7
CKPT Price Earnings VS Forward Price EarningsCKPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CKPT Per share dataCKPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CKPT's earnings are expected to grow with 85.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.51%
EPS Next 3Y85.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CKPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHECKPOINT THERAPEUTICS INC

NASDAQ:CKPT (5/29/2025, 8:00:00 PM)

After market: 4.2705 +0.01 (+0.25%)

4.26

+0.03 (+0.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11
Inst Owners37.08%
Inst Owner Change-2.11%
Ins Owners0.2%
Ins Owner Change-4505.02%
Market Cap370.71M
Analysts77.78
Price Target4.42 (3.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-154.89%
Min EPS beat(2)-256.04%
Max EPS beat(2)-53.74%
EPS beat(4)1
Avg EPS beat(4)-71.5%
Min EPS beat(4)-256.04%
Max EPS beat(4)42.14%
EPS beat(8)3
Avg EPS beat(8)-41.96%
EPS beat(12)5
Avg EPS beat(12)-34.73%
EPS beat(16)6
Avg EPS beat(16)-35.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-63.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.53%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.7
P/S 9041.59
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)1.15
Fwd EY27.06%
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0
BVpS-0.15
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -752.78%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-729.34%
ROA(5y)-468.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.37
Quick Ratio 0.37
Altman-Z -85.21
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.42%
EPS Next Y87.52%
EPS Next 2Y67.51%
EPS Next 3Y85.74%
EPS Next 5Y31.84%
Revenue 1Y (TTM)-60.19%
Revenue growth 3Y-46.65%
Revenue growth 5Y-52.58%
Sales Q2Q%N/A
Revenue Next Year300659%
Revenue Next 2Y11555.7%
Revenue Next 3Y3960.1%
Revenue Next 5Y711.65%
EBIT growth 1Y-7.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.65%
OCF growth 3YN/A
OCF growth 5YN/A